These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Clinicopharmacological studies of a newly synthesized cardiotonic agent (TA-064) in patients with congestive heart failure. Bito K; Kinoshita M; Mashiro I; Ozaki N; Sakoda S; Tsutamoto T; Motomura M; Mitsunami K; Fukuhara T; Kawakita S Clin Cardiol; 1988 May; 11(5):334-9. PubMed ID: 3383472 [TBL] [Abstract][Full Text] [Related]
30. A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure. Jamieson MJ; Webster J; Fowler G; Rawles J; Smith FW; Petrie JC Br J Clin Pharmacol; 1991 Mar; 31(3):305-12. PubMed ID: 1675867 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular pharmacology of dopexamine in low output congestive heart failure. Leier CV; Binkley PF; Carpenter J; Randolph PH; Unverferth DV Am J Cardiol; 1988 Jul; 62(1):94-9. PubMed ID: 2898209 [TBL] [Abstract][Full Text] [Related]
32. Renal and systemic hemodynamic effects of ibopamine in patients with mild to moderate congestive heart failure. Lieverse AG; van Veldhuisen DJ; Smit AJ; Zijlstra JG; Meijer S; Reitsma WD; Lie KI; Girbes AR J Cardiovasc Pharmacol; 1995 Mar; 25(3):361-7. PubMed ID: 7769799 [TBL] [Abstract][Full Text] [Related]
33. Comparison of cardiorenal and emetic effects of dopamine prodrugs docarpamine (TA-870) and levodopa in dogs. Nishiyama S; Kanno K; Yamaguchi I J Pharmacobiodyn; 1991 Mar; 14(3):120-5. PubMed ID: 1679131 [TBL] [Abstract][Full Text] [Related]
34. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Townend JN; Doran J; Lote CJ; Davies MK Br Heart J; 1995 May; 73(5):434-41. PubMed ID: 7786658 [TBL] [Abstract][Full Text] [Related]
35. Dopexamine hydrochloride in chronic congestive heart failure with improved cardiac performance without increased metabolic cost. De Marco T; Kwasman M; Lau D; Chatterjee K Am J Cardiol; 1988 Aug; 62(5):57C-62C. PubMed ID: 3407596 [TBL] [Abstract][Full Text] [Related]
37. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Boerrigter G; Costello-Boerrigter LC; Cataliotti A; Tsuruda T; Harty GJ; Lapp H; Stasch JP; Burnett JC Circulation; 2003 Feb; 107(5):686-9. PubMed ID: 12578869 [TBL] [Abstract][Full Text] [Related]
38. Double-blind haemodynamic study of a new dopamine derivative (diisobutyric ester of N-methyl-dopamine) orally active in chronic congestive heart failure. Mengeot P; Piette F; Mirgaux M G Ital Cardiol; 1981; 11(11):1738-42. PubMed ID: 7343377 [No Abstract] [Full Text] [Related]
39. The renal effects of low-dose dopamine in thermally injured patients. Graves TA; Cioffi WG; Vaughan GM; Pratt L; Heironimus JD; McManus WF; Pruitt BA J Trauma; 1993 Jul; 35(1):97-102; discussion 102-3. PubMed ID: 8331720 [TBL] [Abstract][Full Text] [Related]
40. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: comparison of effects with those of endothelin A receptor antagonism. Wada A; Tsutamoto T; Ohnishi M; Sawaki M; Fukai D; Maeda Y; Kinoshita M Circulation; 1999 Feb; 99(4):570-7. PubMed ID: 9927406 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]